Do analysts recommend ANEB or CLNN?

Clene has a consensus target price of $33.25, suggesting a potential upside of 479.27%. Given Clene's stronger consensus rating and higher possible upside, analysts clearly believe Clene is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Do analysts prefer LONA or ANEB?

Athira Pharma presently has a consensus price target of $15.00, suggesting a potential upside of 74.62%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better valuation & earnings, LONA or ANEB?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$5.21 N/A Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is LONA or ANEB more profitable?

Anebulo Pharmaceuticals' return on equity of -74.57% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -381.01% -225.74% Anebulo Pharmaceuticals N/A -74.57% -68.96%

Do analysts rate ANEB or PLRX?

Pliant Therapeutics has a consensus price target of $3.00, indicating a potential upside of 165.49%. Given Pliant Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pliant Therapeutics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Pliant Therapeutics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80

Is ANEB or PLRX more profitable?

Pliant Therapeutics' return on equity of -58.11% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Anebulo Pharmaceuticals N/A -74.57% -68.96% Pliant Therapeutics N/A -58.11% -44.37%

Do analysts prefer HRTX or ANEB?

Heron Therapeutics currently has a consensus price target of $2.50, suggesting a potential upside of 474.71%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Heron Therapeutics is more favorable than Anebulo Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 2 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend XBIT or ANEB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation and earnings, XBIT or ANEB?

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XBiotech N/A N/A -$45.54M -$1.32 N/A Anebulo Pharmaceuticals N/A N/A -$8.48M -$0.19 N/A

Is XBIT or ANEB more profitable?

XBiotech's return on equity of -26.10% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -26.10% -25.06% Anebulo Pharmaceuticals N/A -74.57% -68.96%

Anebulo Pharmaceuticals (ANEB) Competitors

$0.40 0.00 (-0.20%)

As of 10:18 AM Eastern

Compare

ANEB vs. CLNN, LONA, PLRX, HRTX, and XBIT

Should you buy Anebulo Pharmaceuticals stock or one of its competitors? MarketBeat compares Anebulo Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anebulo Pharmaceuticals include Clene (CLNN), Athira Pharma (LONA), Pliant Therapeutics (PLRX), Heron Therapeutics (HRTX), and XBiotech (XBIT). These companies are all part of the "pharmaceutical products" industry.

How does Anebulo Pharmaceuticals compare to Clene?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Anebulo Pharmaceuticals has a beta of -1.88, indicating that its stock price is 288% less volatile than the broader market. Comparatively, Clene has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Anebulo Pharmaceuticals has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Clene	-25,009.70%	N/A	-137.98%

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by insiders. Comparatively, 28.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Clene has a consensus target price of $33.25, suggesting a potential upside of 479.27%. Given Clene's stronger consensus rating and higher possible upside, analysts clearly believe Clene is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Anebulo Pharmaceuticals has higher earnings, but lower revenue than Clene. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Clene	$200K	366.79	-$26.17M	-$3.20	N/A

In the previous week, Clene had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 1 mentions for Clene and 0 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 0.00 equaled Clene'saverage media sentiment score.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
Clene	Neutral

Summary

Clene beats Anebulo Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

In the previous week, Athira Pharma had 2 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 2 mentions for Athira Pharma and 0 mentions for Anebulo Pharmaceuticals. Athira Pharma's average media sentiment score of 0.34 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Athira Pharma	Neutral
Anebulo Pharmaceuticals	Neutral

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Athira Pharma presently has a consensus price target of $15.00, suggesting a potential upside of 74.62%. Given Athira Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Athira Pharma is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Athira Pharma has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.88, indicating that its stock price is 288% less volatile than the broader market.

Anebulo Pharmaceuticals' return on equity of -74.57% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Summary

Athira Pharma beats Anebulo Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Pliant Therapeutics?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Pliant Therapeutics' return on equity of -58.11% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Pliant Therapeutics	N/A	-58.11%	-44.37%

Pliant Therapeutics has a consensus price target of $3.00, indicating a potential upside of 165.49%. Given Pliant Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pliant Therapeutics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

Anebulo Pharmaceuticals has higher earnings, but lower revenue than Pliant Therapeutics. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Pliant Therapeutics	$1.58M	44.28	-$149.34M	-$1.84	N/A

In the previous week, Anebulo Pharmaceuticals' average media sentiment score of 0.00 equaled Pliant Therapeutics'average media sentiment score.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
Pliant Therapeutics	Neutral

28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Comparatively, 8.0% of Pliant Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Anebulo Pharmaceuticals has a beta of -1.88, suggesting that its share price is 288% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

Summary

Pliant Therapeutics beats Anebulo Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

Anebulo Pharmaceuticals has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Anebulo Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.53	-$20.19M	-$0.18	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Heron Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.88, suggesting that its stock price is 288% less volatile than the broader market.

Heron Therapeutics currently has a consensus price target of $2.50, suggesting a potential upside of 474.71%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Heron Therapeutics is more favorable than Anebulo Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Anebulo Pharmaceuticals has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Anebulo Pharmaceuticals' return on equity of -74.57% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Heron Therapeutics' average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Heron Therapeutics	Neutral
Anebulo Pharmaceuticals	Neutral

Summary

Heron Therapeutics beats Anebulo Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Anebulo Pharmaceuticals compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

XBiotech's return on equity of -26.10% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-26.10%	-25.06%
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%

XBiotech has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.88, meaning that its stock price is 288% less volatile than the broader market.

In the previous week, XBiotech had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 1 mentions for XBiotech and 0 mentions for Anebulo Pharmaceuticals. XBiotech's average media sentiment score of 0.67 beat Anebulo Pharmaceuticals' score of 0.00 indicating that XBiotech is being referred to more favorably in the media.

Company	Overall Sentiment
XBiotech	Positive
Anebulo Pharmaceuticals	Neutral

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

XBiotech beats Anebulo Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Get Anebulo Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANEB vs. The Competition

Export

Metric	Anebulo Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.11M	$3.51B	$6.56B	$12.24B
Dividend Yield	N/A	2.30%	2.69%	5.82%
P/E Ratio	-2.08	20.68	25.17	23.98
Price / Sales	N/A	336.69	553.76	120.62
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.41	8.26	10.76	6.41
Net Income	-$8.48M	$23.91M	$3.56B	$337.14M
7 Day Performance	-14.13%	3.05%	1.37%	-0.48%
1 Month Performance	-14.13%	2.40%	0.81%	0.49%
1 Year Performance	-73.67%	56.35%	30.53%	28.16%

Anebulo Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
ANEB Anebulo Pharmaceuticals	N/A	$0.40 -0.2%	N/A	-74.0%	$16.11M	N/A	N/A	4
CLNN Clene	3.081 of 5 stars	$5.93 +1.4%	$33.25 +460.7%	+40.7%	$74.75M	$200K	N/A	100
LONA Athira Pharma	3.7141 of 5 stars	$8.23 +4.4%	$15.00 +82.3%	N/A	$74.02M	N/A	N/A	40
PLRX Pliant Therapeutics	1.6602 of 5 stars	$1.18 -0.8%	$3.00 +154.2%	-7.2%	$73.68M	$1.58M	N/A	90
HRTX Heron Therapeutics	1.4143 of 5 stars	$0.39 +1.4%	$2.50 +545.5%	-80.2%	$72.31M	$154.90M	N/A	300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANEB) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anebulo Pharmaceuticals (ANEB) Competitors

ANEB vs. CLNN, LONA, PLRX, HRTX, and XBIT

How does Anebulo Pharmaceuticals compare to Clene?

Summary

How does Anebulo Pharmaceuticals compare to Athira Pharma?

Summary

How does Anebulo Pharmaceuticals compare to Pliant Therapeutics?

Summary

How does Anebulo Pharmaceuticals compare to Heron Therapeutics?

Summary

How does Anebulo Pharmaceuticals compare to XBiotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB vs. The Competition

Anebulo Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anebulo Pharmaceuticals (ANEB) Competitors

ANEB vs. CLNN, LONA, PLRX, HRTX, and XBIT

How does Anebulo Pharmaceuticals compare to Clene?

Which has more volatility & risk, ANEB or CLNN?

Is ANEB or CLNN more profitable?

Do institutionals & insiders hold more shares of ANEB or CLNN?

Do analysts recommend ANEB or CLNN?

Which has stronger valuation & earnings, ANEB or CLNN?

Does the media favor ANEB or CLNN?

Summary

How does Anebulo Pharmaceuticals compare to Athira Pharma?

Does the media refer more to LONA or ANEB?

Do institutionals and insiders hold more shares of LONA or ANEB?

Do analysts prefer LONA or ANEB?

Which has more volatility and risk, LONA or ANEB?

Is LONA or ANEB more profitable?

Which has better valuation & earnings, LONA or ANEB?

Summary

How does Anebulo Pharmaceuticals compare to Pliant Therapeutics?

Is ANEB or PLRX more profitable?

Do analysts rate ANEB or PLRX?

Which has stronger valuation & earnings, ANEB or PLRX?

Does the media refer more to ANEB or PLRX?

Do insiders and institutionals believe in ANEB or PLRX?

Which has more volatility & risk, ANEB or PLRX?

Summary

How does Anebulo Pharmaceuticals compare to Heron Therapeutics?

Which has better earnings and valuation, HRTX or ANEB?

Which has more risk & volatility, HRTX or ANEB?

Do analysts prefer HRTX or ANEB?

Is HRTX or ANEB more profitable?

Do institutionals & insiders hold more shares of HRTX or ANEB?

Does the media prefer HRTX or ANEB?

Summary

How does Anebulo Pharmaceuticals compare to XBiotech?

Do insiders and institutionals believe in XBIT or ANEB?

Is XBIT or ANEB more profitable?

Which has more risk & volatility, XBIT or ANEB?

Does the media prefer XBIT or ANEB?

Which has higher valuation and earnings, XBIT or ANEB?

Do analysts recommend XBIT or ANEB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANEB vs. The Competition

Anebulo Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools